Quality of women’s life in perimenopause – possibilities of non-hormonal correction

Authors

  • T.F. Tatarchuk SI «All-Ukrainian Center of Maternity and Childhood of the NAMS of Ukraine»; SSI «Center of Innovative Medical Technologies of the NAS of Ukraine», Kyiv, Ukraine https://orcid.org/0000-0002-5498-4143
  • S.I. Regeda SI «All-Ukrainian Center of Motherhood and Childhood of the NAMS of Ukraine»; SSI «Center of Innovative Medical Technologies of the NAS of Ukraine», Kyiv, Ukraine https://orcid.org/0000-0002-4960-7175
  • N.V. Kosei SI «All-Ukrainian Center of Motherhood and Childhood of the NAMS of Ukraine»; SSI «Center of Innovative Medical Technologies of the NAS of Ukraine», Kyiv, Ukraine https://orcid.org/0000-0003-3085-3285
  • N.F. Zakharenko SI «All-Ukrainian Center of Motherhood and Childhood of the NAMS of Ukraine», Kyiv, Ukraine https://orcid.org/0000-0003-2934-3157
  • T.Е. Krysenko SI «All-Ukrainian Center of Motherhood and Childhood of the NAMS of Ukraine»; Taras Shevchenko National University of Kyiv, Kyiv, Ukraine https://orcid.org/0009-0003-1934-3687

DOI:

https://doi.org/10.18370/2309-4117.2024.74.31-38

Keywords:

perimenopause, magnesium, melatonin, climacteric syndrome, sleep disorders, Metida, Melani

Abstract

Objective of the study: to evaluate the effectiveness of antistress therapy and sleep quality improvement on the course of climacteric syndrome (CS) and quality of life of perimenopausal women.
Materials and methods: The study included 90 women aged 42–55 with moderate CS. Group I consisted of 30 women receiving Metida (elemental magnesium 300 mg, vitamin B6 30 mg), Group II included 30 women treated with Melani (two-stage release melatonin 2,95 mg), and Group III received combined therapy with both drugs. Patients underwent testing using the Spielberg-Hanin scale and PSM-25 scale before treatment, after 1 and 3 months of therapy, and SF-36, MRS, PSQI, ESS scales at baseline and after 3 months of therapy. Follicle-stimulating hormone (FSH) and prolactin levels were assessed at the study’s start, with FSH measured again after 3 months.
Results. Magnesium effectively reduced situational and trait anxiety in women with CS after 3 months of therapy; however, a similar effect was achieved within 1 month when it was combined with melatonin. The combined administration of magnesium and melatonin significantly reduced psychological stress levels from high to moderate according to PSM-25 scale (107.5 ± 8.6 compared to 167 ± 9.6; p < 0.05). Combined therapy also substantially improved the quality of life, particularly in psychological well-being and overall health perception according to SF-36 questionnaire. Symptoms of CS, as assessed by the MRS scale, significantly decreased within 1 month of melatonin monotherapy for psychological symptoms, with somatovegetative symptoms improving by 3 months. Combined therapy improved both symptom components within 1 month, but the difference was likely to be significant at 3 months compared to the 1-month examination (2.1 ± 0.34 and 2.6 ± 0.22 compared to 4.4 ± 0.42 and 3.7 ± 0.49, respectively; p < 0.05). Combined therapy with magnesium and melatonin significantly lowered FSH levels after 3 months (31.6 ± 6.3 vs. 44.1 ± 7.1; p < 0.05). Enhanced sleep quality, depth, and duration were noted within 3 months of combined therapy without causing daytime sleepiness.
Conclusions. The two-stage release melatonin reduces CS symptoms by improving sleep quality, lowering psychomotional symptoms, and reducing psychological stress. Combined therapy with magnesium and melatonin positively affects the hypothalamic-pituitary-ovarian axis, significantly alleviating psychomotional symptoms of CS and adjusting the somatovegetative component by enhancing sleep quality and depth, reducing psychological stress, and improving overall health perception.

Author Biographies

T.F. Tatarchuk, SI «All-Ukrainian Center of Maternity and Childhood of the NAMS of Ukraine»; SSI «Center of Innovative Medical Technologies of the NAS of Ukraine», Kyiv

MD, professor, corresponding member of the National Academy of Medical Sciences of Ukraine, head of the Department of Endocrine Gynecology;
Chief researcher, Reproductive Health Department

S.I. Regeda, SI «All-Ukrainian Center of Motherhood and Childhood of the NAMS of Ukraine»; SSI «Center of Innovative Medical Technologies of the NAS of Ukraine», Kyiv

PhD, senior researcher, Department of Endocrine Gynecology;
Head of the Gynecology Department

N.V. Kosei, SI «All-Ukrainian Center of Motherhood and Childhood of the NAMS of Ukraine»; SSI «Center of Innovative Medical Technologies of the NAS of Ukraine», Kyiv

MD, professor, chief researcher, Department of Endocrine Gynecology;
Head of the Reproductive Health Department

N.F. Zakharenko, SI «All-Ukrainian Center of Motherhood and Childhood of the NAMS of Ukraine», Kyiv

MD, professor, chief researcher, Department of Endocrine Gynecology

T.Е. Krysenko, SI «All-Ukrainian Center of Motherhood and Childhood of the NAMS of Ukraine»; Taras Shevchenko National University of Kyiv, Kyiv

Obstetrician-gynecologist;
Assistant, Department of Pediatrics, Obstetrics and Gynecology

References

  1. Order of the Ministry of Health of Ukraine dated 17.06.2022 No. 1039 «Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care «Menopausal disorders and other disorders in the perimenopausal period». [Internet]. Ministry of Health of Ukraine. 2022. Available from: https://www. dec.gov.ua/wp-content/uploads/2022/06/37474-dn_1039_17_06_2022_dod.pdf
  2. Bansal R, Aggarwal N. Menopausal Hot Flashes: A Concise Review. Journal of mid-life health. 2019 Jan-Mar;10(1):6-13. DOI: 10.4103/jmh.JMH_7_19
  3. Pinkerton JV, Abraham L, Bushmakin AG, et al. Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters. Menopause. 2016;23(10):1060–6. DOI: 10.1097/GME.0000000000000678.
  4. Freeman EW, Sammel MD, Gross SA, Pien GW. Poor sleep in relation to natural menopause: a population-based 14-year follow-up of midlife women. Menopause. 2015;22(7):719–26. DOI: 10.1097/GME.0000000000000392
  5. Baker FC, Willoughby AR, Sassoon SA, et al. Insomnia in women approaching menopause: beyond perception. Psychoneuroendocrinology. 2015;60:96–104. DOI: 10.1016/j.psyneuen.2015.06.005
  6. Salari, N., Hasheminezhad, R., Hosseinian-Far, A. et al. Global prevalence of sleep disorders during menopause: a meta-analysis. Sleep Breath 27, 1883–97 (2023). DOI: 10.1007/s11325-023-02793-5
  7. Djapardy V, Panay N. Alternative and non-hormonal treatments to symptoms of menopause. Best Pract Res Clin Obstet Gynaecol. 2022 May;81:4–-60. DOI: 10.1016/j.bpobgyn.2021.09.012.
  8. Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS. Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19:109–150. DOI: 10.3109/13697137.2015.1129166
  9. Guida M, Raffone A, Travaglino A, et al. Cimicifuga racemosa isopropanolic extract for menopausal symptoms: an observational prospective case–control study. Gynecol Endocrinol. 2021 Dec;37(12):1132-7. DOI: 10.1080/09513590.2021.1974381
  10. Hairi HA, Shuid AN, Ibrahim N‘I, et al. The Effects and Action Mechanisms of Phytoestrogens on Vasomotor Symptoms During Menopausal Transition: Thermoregulatory Mechanism. Curr Drug Targets. 2019;20(2):192–200. DOI: 10.2174/1389450118666170816123740
  11. Capozzi A, Scambia G, Lello S. Calcium, vitamin D, vitamin K2, and magnesium supplementation and skeletal health. Maturitas. 2020 Oct;140:55–63. DOI: 10.1016/jmaturitas.2020.05.
  12. Madaeva I, Semenova N, Zhambalova RM, et al. Polysomnographic pattern of melatonin therapy in perimenopausal women. Inter J Biomed. 2020;10:161–4. DOI:10.21103/Article10(2)_OA15
  13. Walecka-Kapica E, Klupinska G, Chojnacki J, et al. The effect of melatonin supplementation on the quality of sleep and weight status in postmenopausal women. Prz Menopauzalny. 2014;13:334–8. DOI: 10.5114/pm.2014.47986
  14. Toffol E, Kalleinen N, Haukka J, et al. Melatonin in perimenopausal and postmenopausal women: associations with mood, sleep, climacteric symptoms, and quality of life. Menopause. 2014.21(5): 493–500. DOI: 10.1097/GME.0b013e3182a6c8f3
  15. Amstrup AK, Sikjaer T, Mosekilde L, Rejnmark L. The effect of melatonin treatment on postural stability, muscle strength, and quality of life and sleep in postmenopausal women: a randomized controlled trial. Nutr J. 2015;14:102. DOI: 10.1186/s12937-015-0093-1.
  16. Kayacik AD, İlcioglu K. Effects of melatonin intake on depression and anxiety in postmenopausal women: a systematic review and meta-analysis of randomised controlled trials. Arch Womens Ment Health. 2024;27(2):265–73. DOI: 10.1007/s00737-023-01395-0
  17. Parandavar N, Abdali K, Keshtgar S, et al. The Effect of Melatonin on Climacteric Symptoms in Menopausal Women; A Double-Blind, Randomized Controlled, Clinical Trial. Iran J Public Health. 2014 Oct;43(10):1405–16.
  18. Jehan S, Jean-Louis G, Zizi F, et al. Sleep, Melatonin, and the Menopausal Transition: What Are the Links? Sleep Sci. 2017;10:11–8. DOI: 10.5935/1984-0063.20170003
  19. Groenendijk I, van Delft M, Versloot P, et al. Impact of magnesium on bone health in older adults: A systematic review and meta-analysis. Bone. 2022;154:116233. DOI:10.1016/j.bone.2021.116233
  20. Farsinejad-Marj M, Saneei P, Esmaillzadeh A. Dietary magnesium intake, bone mineral density and risk of fracture: a systematic review and meta-analysis. Osteoporos Int. 2016 Apr;27(4):1389–99. DOI: 10.1007/s00198-015-3400-y
  21. Zhao D, Chen P, Chen M, et al. Association of Magnesium Depletion Score with Congestive Heart Failure: Results from the NHANES 2007–2016. Biol Trace Elem Res. 2024. Feb;202(2). 454–65. DOI: 10.1007/s12011-023-03697-x
  22. Pickering G, Mazur A, Trousselard M, et al. Magnesium Status and Stress: The Vicious Circle Concept Revisited. Nutrients. 2020; 12(12):3672. Published 2020 Nov 28. DOI: 10.3390/nu12123672
  23. Boyle NB, Lawton C, Dye L. The Effects of Magnesium Supplementation on Subjective Anxiety and Stress-A Systematic Review. Nutrients. 2017;9(5):429. DOI: 10.3390/nu9050429
  24. Carlos RM, Matias CN, Cavaca ML, et al. The effects of melatonin and magnesium in a novel supplement delivery system on sleep scores, body composition and metabolism in otherwise healthy individuals with sleep disturbances. Chronobiol Int. 2024;41(6):817–28. DOI: 10.1080/07420528.2024.2353225
  25. Heinemann K, Ruebig A, Potthoff P, et al. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes. 2004 Sep 2;2:45. DOI: 10.1186/1477-7525-2-45.
  26. Pretorius TB, Padmanabhanunni A. Anxiety in Brief: Assessment of the Five-Item Trait Scale of the State-Trait Anxiety Inventory in South Africa. Int J Environ Res Public Health. 2023 May 1;20(9):5697. DOI: 10.3390/ijerph20095697.
  27. Busija L, Pausenberger E, Haines TP, et al. Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S383-412. DOI: 10.1002/acr.20541.
  28. Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res.1989;28(2):193–213. DOI: 10.1016/0165-1781(89)90047-4
  29. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–5. DOI: 10.1093/sleep/14.6.54

Downloads

Published

2024-11-29

How to Cite

Tatarchuk, T., Regeda, S., Kosei, N., Zakharenko, N., & Krysenko, T. (2024). Quality of women’s life in perimenopause – possibilities of non-hormonal correction. REPRODUCTIVE ENDOCRINOLOGY, (74), 31–38. https://doi.org/10.18370/2309-4117.2024.74.31-38

Issue

No. 74 (2024)

Section

Management of menopause

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.